1,807 reports of this reaction
3.6% of all AMOXICILLIN AND CLAVULANATE POTASSIUM reports
#2 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #2 most commonly reported adverse reaction for AMOXICILLIN AND CLAVULANATE POTASSIUM, manufactured by Allegis Holdings, LLC. There are 1,807 FDA adverse event reports linking AMOXICILLIN AND CLAVULANATE POTASSIUM to DRUG HYPERSENSITIVITY. This represents approximately 3.6% of all 50,339 adverse event reports for this drug.
Patients taking AMOXICILLIN AND CLAVULANATE POTASSIUM who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among AMOXICILLIN AND CLAVULANATE POTASSIUM users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for AMOXICILLIN AND CLAVULANATE POTASSIUM:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 1,807 FDA reports for AMOXICILLIN AND CLAVULANATE POTASSIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 3.6% of all adverse event reports for AMOXICILLIN AND CLAVULANATE POTASSIUM, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking AMOXICILLIN AND CLAVULANATE POTASSIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.